Skip to main content
OpenTrials
Completed

NCT Number: NCT01210157

Galectin-3 Binding Protein in Cardiovascular Disease and Chronic Heart Failure

The purpose of this study is to determine whether galectin-3 binding protein plasma levels can predict adverse cardiovascular events in patients with coronary artery disease and/or heart failure.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Heidelberg, Dept. of Cardiology

Heidelberg, 69120, Germany

About this study

Chronic heart failure represents an important cause of disease burden in Western countries. Heart failure can be either caused by vascular disease (i.e. cardiomypathy (CMP) due to coronary artery disease ("ischemic/ICMP")) or by myocardial conditions (i.e. dilated cardiomyopathies (DCMP) resulting from other causes like familial disposition, drug toxicity, etc.). Gold standard for the diagnosis of CMPs is the coronary angiography in conjunction with left ventricular angiography and myocardial biopsy, non-invasive markers include C-reactive protein (CRP) for ICMP and brain natriuretic protein (BNP) for DCMP. We have previously identified G3BP to be overexpressed in foam cells and plasma-derived microparticles, both potentially important in formation of atherosclerotic plaque. Galectin-3 binding protein (G3BP) is a secreted protein that is involved in cell adhesion and immune activation. The purpose of the current study is to test, whether G3BP plasma levels (a) are able to non-invasively differentiate causes of CMP and (b) are a suitable means for future risk assessment in CMP patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • impaired ventricular function

Exclusion criteria

  • neoplastic disease
  • infections with hepatitis C or HIV

Treatment and study plan

Primary outcomes

  1. Death from cardiac causes

    Time frame: up to five years

Secondary outcomes

  1. diagnosis of coronary artery disease (CAD)

    Time frame: up to five years

  2. diagnosis of cardiomypathy (CMP)

    Time frame: up to five years

  3. assessment of disease stage (CAD-1-3, NYHA I-IV)

    Time frame: up to five years

  4. non-fatal myocardial infarction or cerebrovascular accident

    Time frame: up to five years

  5. revascularization (percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG))

    Time frame: up to five years

  6. rehospitalization

    Time frame: up to five years

  7. implantation of ICD/biventricular pacemaker

    Time frame: up to five years

  8. heart transplantation

    Time frame: up to five years

  9. correlation with patient history

    Time frame: up to five years

  10. correlation with physical examination

    Time frame: up to five years

  11. correlation with routine lab values

    Time frame: up to five years

  12. correlation with ECG

    Time frame: up to five years

  13. correlation with echocardiography

    Time frame: up to five years

  14. correlation with cardiac MRI

    Time frame: up to five years

  15. correlation with cardiac CT

    Time frame: up to five years

  16. correlation with chest X-ray

    Time frame: up to five years

Sponsors and collaborators

Lead sponsor

Heidelberg University

Other

Registry information

Official study title

GALectin-3 Binding Protein for Risk Assessment in Coronary arTery dIsease and Chronic Heart Failure

Acronym: GALACTIC

Important dates

Study start
2008
Primary completion
2008
Study completion
2010
First posted
Sep 28, 2010
Registry last updated
Sep 28, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.